Thursday 20 December 2012
Vismodegib acts as a cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part of the hedgehog signaling pathway (SHH pathway). Cyclopamine is a naturally occurring SMO antagonist.
This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas.
Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC).
The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval.
The drug was developed by the biotechnology / pharmaceutical company Genentech, which is headquartered at South San Francisco, California, USA.
Vismodegib is indicated for patients with basal cell carcinoma (BCC), which has metastasized to other parts of the body, relapsed after surgery, or cannot be treated with surgery or radiation.